Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The rationale for this study is to provide additional treatment with NEOD001 for subjects who
complete Study NEOD001-001, and to continue to evaluate long term safety and tolerability.
All subjects in the current NEOD001 trials are being dosed at 24 mg/kg, which will be
continued in this study.